Pregled bibliografske jedinice broj: 668547
Završni stadij kronične bubrežne bolesti u starijih
Završni stadij kronične bubrežne bolesti u starijih // Acta medica Croatica. Supplement, 66 (2012), supplement2; 22-36 (podatak o recenziji nije dostupan, pregledni rad, stručni)
CROSBI ID: 668547 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Završni stadij kronične bubrežne bolesti u starijih
(End-stage renal disease in elderly)
Autori
Kes, P ; Jukić, NB ; Jurić, I ; Brunetta, BB
Izvornik
Acta medica Croatica. Supplement (1331-1638) 66
(2012), Supplement2;
22-36
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni
Ključne riječi
završni stadij bubrežne bolesti; starija populacija; mogućnosti liječenja
(end-stage renal disease; elderly; treatment possibilities)
Sažetak
The balance and quality of different renal replacement treatment modalities used in the elderly with end-stage renal disease vary between countries depending on economic resources, distribution of renal units, number of specialists, and patterns of reimbursement of both hospitals and physicians. Elderly patients with end-stage renal disease need detailed assessment of medical, psychological, motor, and social factors in order to choose an appropriate renal replacement treatment option. Presence or absence of significant comorbidity is much more important than the chronological age. The choice between hemodialysis and continuous ambulatory peritoneal dialysis is largely dependant on preferences of the local team and the patient. Patients with adequate cardiovascular systems are generally considered to be more suitable for hemodialysis. Hemoglobin should be optimized (Hb between 100 and 120 g/L) in all patients. Poor cardiac status and/or angina will require assessment, medical treatment, and, if necessary, surgical treatment or angioplasty. Transplantation should be considered in all reasonably fit and carefully selected patients older than 65 or even 70 years. Only the permanent shortage of suitable kidneys limits our ability to treat all those who could benefit from this type of treatment. Renal transplant recipients may benefit in terms of both survival and quality of life even if older than 70 years and beyond. Immunosuppressive therapy in elderly patients should be moderate.
Izvorni jezik
Hrvatski
POVEZANOST RADA
Projekti:
108-0000000-3499 - Prevencija, rano prepoznavanje i liječenje kroničnog zatajenja bubrega (Kes, Petar, MZOS ) ( CroRIS)
108-1080134-0122 - Čimbenici rizika za razvoj ateroskleroze nakon transplantacije bubrega (Bašić-Jukić, Nikolina, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb